ActivBiotics Pharma, LLC
http://www.activbioticspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ActivBiotics Pharma, LLC
Bidding War As China Opens Up $2Bn COVID-19 Antigen Test Market
After the recent spike in COVID-19, China has allowed the public to buy rapid antigen home-use tests. Prices offered in a recent government tender were cut by over 50% as local manufacturers rushed meet the demand opportunity.
Deals Shaping The Medical Industry, September 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Medical Device Deals Update, August 2012
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Inhibikase Therapeutics elects Steven Gilman to board
Inhibikase Therapeutics, a creator of anti-infective therapies, has elected Dr Steven Gilman to its board of directors. Dr Gilman currently serves as executive vice-president, R&D and chief scientific officer at Cubist Pharmaceuticals. Prior to this, he was chairman, president and CEO of ActivBiotics.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice